2024
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
Carbone M, Neuberger J, Rowe I, Polak W, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu G, Strazzabosco M, Cillo U. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transplant International 2024, 36: 12190. PMID: 38332850, PMCID: PMC10850237, DOI: 10.3389/ti.2023.12190.Peer-Reviewed Original ResearchMeSH KeywordsHumansLiver TransplantationOrgan TransplantationOutcome Assessment, Health CareValue-Based Health CareConceptsValue-based health careOutcome measuresEuropean Society of Organ TransplantationLiver transplantationDevelopment of outcome measuresConsensus statementOrgan transplantationValue-basedPatient-focusedAdvanced liver diseaseHealth careMultidisciplinary teamLiver diseaseTransplantationLife-savingEuropean Society for Organ TransplantationPatients
2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularGraft RejectionHumansImmune Checkpoint InhibitorsLiver NeoplasmsLiver TransplantationConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
2019
Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma
Kokabi N, Nezami N, Xing M, Ludwig JM, Strazzabosco M, Kim HS. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. Journal Of Comparative Effectiveness Research 2019, 8: 993-1002. PMID: 31512955, DOI: 10.2217/cer-2019-0076.Peer-Reviewed Original ResearchConceptsTransplantation Network/United NetworkOrgan Sharing (UNOS) policyUnited NetworkNew Organ ProcurementHepatocellular carcinomaOrgan procurementOrthotopic liver transplantation outcomesLiver transplantation outcomesOrgan Sharing databaseOverall survivalPatient characteristicsSharing databaseTransplantation outcomesPatientsCarcinomaAMPTransplantationGroup
2018
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C, Association A. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.Peer-Reviewed Original ResearchConceptsHepatitis C virusNon-alcoholic steatohepatitisHepatitis B virusEuropean Liver Transplant RegistryLiver transplantationSurvival of recipientsDAA eraLiver diseaseHepatocellular carcinomaEvolution of indicationsVirus infectionNumber of LTsHepatitis B virus infectionHepatitis C virus infectionAdult liver transplantationAdvent of DAAsImpact of DAAsLiver Transplant RegistrySecond-generation DAAsC virus infectionLiver transplant recipientsOutcomes of patientsB virus infectionThree-year survivalDAA treatmentThe optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2016
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, Association E. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-531. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularHepatitis C, ChronicHumansLiver NeoplasmsLiver TransplantationWaiting ListsConceptsDirect acting antiviralsOral direct acting antiviralsClinical improvementChild-PughLiver transplantationActing antiviralsAdvanced liver diseaseChronic hepatitis CLiver transplant candidatesLow MELD scoresRemarkable clinical improvementHepatitis C virusDAA therapyDelta MELDDelta-albuminDAA combinationsHepatitis CMELD scoreViral eradicationCumulative incidenceLiver dysfunctionTransplant candidatesAntiviral therapyLiver diseaseLiver function
2015
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis
Cortesi P, Mantovani L, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli L. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. American Journal Of Transplantation 2015, 15: 1817-1826. PMID: 26086300, PMCID: PMC4946849, DOI: 10.1111/ajt.13320.Peer-Reviewed Original ResearchRecipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort
Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M, Investigators L. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease 2015, 47: 689-694. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.Peer-Reviewed Original ResearchConceptsRecipient female genderGraft lossFemale genderLiver transplantationRisk factorsEnd-stage liver disease (MELD) scoreFive-year graft survivalStage liver disease scoreOutcome of HCVSevere HCV recurrenceChronic hepatitis CHCV-positive patientsLiver Disease scoreHepatitis C virusHCV recurrenceGraft outcomeGraft survivalHepatitis CPortal thrombosisTransplant recipientsLiver graftsIndependent determinantsRetrospective studyC virusMatch cohort
2014
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study
Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M, Investigators L, Committee: L, Angelico M, Cillo U, Fagiuoli S, Strazzabosco M, Board: A, Caraceni P, Toniutto P, Board: C, Costa A, Investigators: P, Salizzoni T, Romagnoli R, Bertolotti G, Patrono D, De Carlis L, Slim A, Mangoni J, Rossi G, Caccamo L, Antonelli B, Mazzaferro V, Regalia E, Sposito C, Colledan M, Corno V, Tagliabue F, Marin S, Cillo U, Vitale A, Gringeri E, Donataccio M, Donataccio D, Baccarani U, Lorenzin D, Bitetto D, Valente U, Gelli M, Cupo P, Gerunda G, Rompianesi G, Pinna A, Grazi G, Cucchetti A, Zanfi C, Risaliti A, Faraci M, Tisone G, Anselmo A, Lenci I, Sforza D, Agnes S, Di Mugno M, Avolio A, Ettorre G, Miglioresi L, Vennarecci G, Berloco P, Rossi M, Corradini S, Molinaro A, Calise F, Scuderi V, Cuomo O, Migliaccio C, Lupo L, Notarnicola G, Gridelli B, Volpes R, Petri S, Zamboni F, Carbotta G, Dedola S, Collection and Verification and Biostatistics: D, Nardi A, Marianelli T, Gavrila C, Ricci A, Vespasiano F. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive And Liver Disease 2014, 46: 340-347. PMID: 24411484, DOI: 10.1016/j.dld.2013.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBayes TheoremBody Mass IndexCohort StudiesCold IschemiaDelayed Graft FunctionEnd Stage Liver DiseaseFemaleGraft RejectionGraft SurvivalHumansItalyLiver TransplantationMaleMiddle AgedMultivariate AnalysisPrimary Graft DysfunctionProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsTissue DonorsTreatment OutcomeConceptsEarly graft lossGraft lossUnited NetworkLiver transplantationPrior upper abdominal surgeryDonor body mass indexProspective European cohortsUpper abdominal surgeryOrgan Sharing registryPrimary liver transplantCold ischaemia timeBody mass indexRisk indexRecipient creatinineBayesian Cox modelsLiver transplantPortal thrombosisAbdominal surgeryCardiac deathIschaemia timeMass indexDonor ageEuropean cohortOrgan SharingCox model
2012
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study
Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN, Investigators F. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. Journal Of Hepatology 2012, 58: 715-723. PMID: 23201239, DOI: 10.1016/j.jhep.2012.11.025.Peer-Reviewed Original ResearchConceptsHBsAg-negative recipientsHBcAb-positive graftsGraft survivalGraft lossNegative recipientsHBcAb positivityLiver transplantationPositive graftsPositive donorsHepatitis B core antibody-positive donorsDe novo HBV hepatitisAntibody-positive donorsHBcAb-positive donorsHBsAg-positive recipientsPositive donor graftsMatched-cohort studyPortal vein thrombosisDeceased heartHBsAg positivityNegative graftsHBV hepatitisDonor graftsFirst transplantHazard ratioPositive recipients
2010
Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching
Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F, Investigators O. Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. Digestive And Liver Disease 2010, 43: 155-164. PMID: 21185796, DOI: 10.1016/j.dld.2010.11.002.Peer-Reviewed Original ResearchConceptsDonor risk indexObservational cohort studyHepatocellular carcinomaLiver transplantationCohort studyDonor ageVirus infectionDeceased heart-beating donorsHepatitis B core antibodyMedian cold ischaemia timeMedian donor risk indexProspective observational cohort studyEnd-stage liver diseaseHepatitis B virus infectionHepatitis C virus infectionLiver MatchDonor populationItalian transplant centersOlder donor ageViral-related cirrhosisB core antibodyC virus infectionStage liver diseaseB virus infectionHigh-risk donorsPrediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria
De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation 2010, 16: 503-512. PMID: 20373461, DOI: 10.1002/lt.22039.Peer-Reviewed Original ResearchConceptsMilan criteriaProgression rateHepatocellular carcinomaRisk factorsObserved progression rateT2 patientsBarcelona Clinic Liver Cancer (BCLC) algorithmEnd-Stage Liver Disease exceptionOrgan allocationTumor persistence/recurrenceStage T2 patientsT2 hepatocellular carcinomaConsecutive HCC patientsProgression-free survivalChronic liver diseasePersistence/recurrenceDistinct natural historyTreatment of choiceBCLC guidelinesMELD scoreMELD exceptionsLocal therapyTransarterial chemoembolizationLiver diseaseTumor diameter
2008
Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
Nishihori T, Strazzabosco M, Saif MW. Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer 2008, 7: 260-266. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/ccc.2008.n.033.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsColorectal cancerLiver transplantationPatient populationColon cancerDe novo colorectal cancerDe novo malignanciesLong-term immunosuppressionMetastatic colorectal cancerPrimary sclerosing cholangitisInflammatory bowel diseaseMajor health concernChronic rejectionNovo malignanciesProlonged immunosuppressionSclerosing cholangitisPosttransplantation periodBiologic agentsBowel diseaseCombination chemotherapyProphylactic colectomyOverall incidenceCommon malignancyLymphoproliferative disease
2007
Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio‐Pulmonary By‐Pass
Corno V, Dezza M, Lucianetti A, Codazzi D, Carrara B, Pinelli D, Parigi P, Guizzetti M, Strazzabosco M, Melzi M, Gaffuri G, Sonzogni V, Rossi A, Fagiuoli S, Colledan M. Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio‐Pulmonary By‐Pass. American Journal Of Transplantation 2007, 7: 2433-2438. PMID: 17845577, DOI: 10.1111/j.1600-6143.2007.01945.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiopulmonary BypassCystic FibrosisHumansIntraoperative PeriodLiver FailureLiver TransplantationLung DiseasesLung TransplantationMaleTreatment OutcomeConceptsLung-liver transplantationCystic fibrosisExtended right graftsSitu split liversWhole liver graftsEnd-stage lungUse of CPBRight graftSplit liverLung transplantPortal hypertensionRespiratory failureLiver graftsLiver diseaseTherapeutic optionsStage lungTransplantationEffective procedureYoung menPatientsFibrosisGraftRecipientsCPBBasiliximab
2005
Practice of adult liver transplantation in Italy Recommendations of the Italian Association for the Study of the Liver (A.I.S.F.)
Angelico M, Gridelli B, Strazzabosco M, Transplantation F. Practice of adult liver transplantation in Italy Recommendations of the Italian Association for the Study of the Liver (A.I.S.F.). Digestive And Liver Disease 2005, 37: 461-467. PMID: 15893508, DOI: 10.1016/j.dld.2005.03.006.Peer-Reviewed Original ResearchMeSH KeywordsHumansItalyLiver TransplantationLiving DonorsReoperationTissue and Organ ProcurementWaiting ListsConceptsLiver transplantationItalian AssociationLiver diseaseEnd-stage liver diseaseDonor/recipient matchingAdult liver transplantationMinimal listing criteriaDonor liver transplantationLiver transplantation recipientsTransplantation recipientsDisease recurrenceMarginal donorsRecipient matchingClinical managementExperienced hepatologistsTransplant surgeonsWaiting listCenter accreditationCurrent evidenceTransplantationOutcome monitoringListing criteriaHepatologistsDiseaseSurgeons
1998
Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery
Iemmolo R, Rossanese A, Rotilio A, Mattisi G, Gerunda G, Merenda R, Neri D, Crepaldi G, Strazzabosco M. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. Journal Of Hepatology 1998, 28: 518-522. PMID: 9551693, DOI: 10.1016/s0168-8278(98)80329-2.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsLiposomal amphotericin BTransplant recipientsCerebral aspergillosisAmphotericin BLife-threatening complicationsLiposomal amphotericin B.Complication-free survivalRisk of recurrenceSystemic side effectsAspergillus fumigatus infectionLong-term survivalSurgical excisionCase reportFumigatus infectionLimited efficacyCerebrospinal fluidSide effectsMortality rateAmphotericin B.AspergillosisRecipientsSurvivalTreatmentFirst report
1997
Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients
Strazzabosco M, Corneo B, Iemmolo R, Menin C, Gerunda G, Bonaldi L, Merenda R, Neri D, Poletti A, Montagna M, Del Mistro A, Faccioli A, D'Andrea E. Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients. Journal Of Hepatology 1997, 26: 926-934. PMID: 9126809, DOI: 10.1016/s0168-8278(97)80262-0.Peer-Reviewed Original ResearchConceptsPost-transplant lymphoproliferative diseaseLiver transplant recipientsOrthotopic liver transplant recipientsLymphoproliferative diseaseTransplant recipientsDonor originB lymphocytesDonor B lymphocytesEBV-specific probesPost-transplant lymphomaOrthotopic liver transplantEpstein-Barr virus sequencesSolid organ transplantationPossible risk factorsLympho-proliferative diseaseNeoplastic B cellsLiver transplantEBV DNAHepatic hilumProspective studyHodgkin's lymphomaPolymerase chain reactionPotential complicationsRisk factorsReal incidence